Proteomic identification of vanin-1 as a marker of kidney damage in a rat model of type 1 diabetic nephropathy  by Fugmann, Tim et al.
Proteomic identification of vanin-1 as a marker of
kidney damage in a rat model of type 1 diabetic
nephropathy
Tim Fugmann1, Beatrice Borgia1, Csaba Re´ve´sz2, Ma´ria Godo´2, Carol Forsblom3,4, Peter Hamar2,
Harry Holtho¨fer5, Dario Neri1 and Christoph Roesli1
1Department of Chemistry and Applied Biosciences, Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland;
2Department of Medicine, Institute of Pathophysiology, Semmelweis University, Budapest, Hungary; 3Folkha¨lsan Research Center,
Biomedicum Helsinki, Folkha¨lsan Institute of Genetics, Helsinki, Finland; 4Division of Nephrology, Department of Medicine, Helsinki
University Hospital, Helsinki, Finland and 5Department of Pathology, Haartman Institute, University of Helsinki, Helsinki, Finland
At present, the urinary albumin excretion rate is the best
noninvasive predictor for diabetic nephropathy (DN) but
major limitations are associated with this marker. Here,
we used in vivo perfusion technology to establish disease
progression markers in an animal model of DN. Rats
were perfused with a reactive ester derivative of biotin at
various times after streptozotocin treatment. Following
homogenization of kidney tissue and affinity purification of
biotinylated proteins, a label-free mass spectrometry-based
proteomic analysis of tryptic digests identified and relatively
quantified 396 proteins. Of these proteins, 24 and 11 were
found to be more than 10-fold up- or downregulated,
respectively, compared with the same procedure in
vehicle-treated rats. Changes in the expression of
selected differentially regulated proteins were validated
by immunofluorescence detection in kidney tissue from
control and diabetic rats. Immunoblot analysis of pooled
human urine found that concentrations of vanin-1, an
ectoenzyme pantetheinase, distinguished diabetic patients
with macroalbuminuria from those with normal albuminuria.
Uromodulin was elevated in the urine pools of the diabetic
patients, regardless of the degree of albuminuria, compared
with healthy controls. Thus, in vivo biotinylation facilitates
the detection of disease-specific changes in the abundance
of potential biomarker proteins for disease monitoring
and/or pharmacodelivery applications.
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Diabetes mellitus is one of the most common chronic
diseases affecting 285 million patients worldwide. Classically,
diabetes has been divided in two main subtypes type 1
diabetes (T1D) and type 2 diabetes (T2D), as well as
secondary diabetes and some monogenic forms of diabetes.
Although T1D only accounts for 5–10% of patients, its
incidence continues to increase worldwide.1 The suscepti-
bility for the disease is largely inherited, residing predomi-
nantly in two genotypes of the human leukocyte antigen, but
it is largely unknown which factors trigger the onset of
clinical symptoms.2 After disease onset, an autoimmune
reaction results in the destruction of pancreatic b-cells and in
an absolute insulin deficiency.
In the etiopathology of T1D as well as T2D, several
complications are likely to occur. The chronic elevation of
blood glucose levels together with the lack of insulin and
other metabolic consequences leads to damage of blood
vessels, hence called diabetic micro- and macroangiopathy.
Diabetic angiopathy of the capillaries in the kidney glomeruli
is most likely involved in the general diabetic nephropathy
(DN), a progressive kidney disease that is characterized by a
set of structural and functional kidney abnormalities.3
Structural abnormalities include kidney hypertrophy in the
early stage of the disease, continuous overproduction of
extracellular matrix leading to increased glomerular base-
ment membrane thickness, nodular and diffuse glomerulo-
sclerosis, tubular atrophy, and interstitial fibrosis.4 In an early
stage, the functional kidney abnormalities include hyperper-
fusion and intraglomerular hypertension.5 Subsequently,
increasing proteinuria, abnormalities of intraglomerular
pressure regulation, systemic hypertension, and continuous
decrease of glomerular filtration rate characterize DN.6
Currently, the earliest clinical evidence of DN is micro-
albuminuria, which is defined as urinary albumin excretion
between 30 and 300 mg/day. Without specific interventions,
B40% of subjects with T1D progress to the stage of overt
nephropathy (or clinical albuminuria; defined as urinary
albumin excretion 4300 mg/day) over a period of 10–15
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years.7 Once overt nephropathy occurs, the glomerular
filtration rate gradually falls over a period of several years if
no specific treatment is started. Finally, an estimated 30–40%
of type 1 diabetic patients with DN will develop end-stage
renal disease within 10 years. These patients then depend on
renal replacement therapy, such as peritoneal dialysis,
hemodialysis, and renal transplantation.8
At present, the urinary albumin excretion rate (UAER) is
the best noninvasive predictor for DN but major limitations
are associated with this marker. Although microalbuminuria
indicates declining kidney function, it is at the same time
an independent risk factor for cardiovascular disease.9
Furthermore, the presence of microalbuminuria by itself
is no adequate indicator for disease progression because of
the observation that 64% of 170 T1D patients reverted
to normoalbuminuria without treatment within a 5-year
period.10 The same study concluded that only glomerular
basement membrane thickening and increased glomerular
filtration rate are predictors for disease progression. Finally, the
occurrence of microalbuminuria in T1D can be associated with
DN lesions comparable to the ones in overt albuminuria.11
To better understand the various pathophysiological
features of DN and to identify potential biomarkers able to
detect DN disease progression or response to therapy, a
number of proteomics investigations have been carried out in
the last years. The availability of rodent models of T1D and
its complications, such as rats with streptozotocin (STZ)-
induced DN12 and OVE26 transgenic mice,13 facilitate these
investigations. Sharma et al.14 have analyzed the urinary
proteome of patients with DN and healthy controls, resulting
in the identification of alpha-1 antitrypsin being 19-fold
upregulated in the diabetic group. In another study, the
C-reactive protein has been identified as possible serum
biomarker when comparing STZ-induced diabetic rats with
healthy controls.15 The comparison of whole-kidney lysates
derived from OVE26 transgenic mice with the ones of
background FVB non-diabetic mice allowed the identifica-
tion of tubulointerstitial elastin depositions in DN and
indicated the potential value of proteomics analyses in
defining features of the pathophysiological processes in
diabetes.16 Furthermore, techniques for the proteomics-based
identification of differentially expressed proteins in glomeruli
from mouse kidneys and human biopsies were developed,
either embolizing magnetic beads into the glomerular
capillaries, followed by magnetic separation of bead-filled
glomeruli or by laser capture microdissection, respectively.17
Finally, the analysis of cultured podocytes grown under
different glucose concentrations contributed to the identifi-
cation of novel targets involved in DN.18
To establish new vascular markers of pathology, our group
has previously used chemical proteomic techniques, based
either on the in vivo perfusion of tumor-bearing animals19–22
or on the ex vivo perfusion of surgically resected human
organs with cancer,23,24 followed by the subsequent capture
of biotinylated proteins on streptavidin resin. These studies
revealed that the in vivo perfusion procedure facilitates
the study of the vascular proteome in cancer, allowing the
identification of markers of angiogenesis, which can be
drugged with monoclonal antibodies.25
In this study, we used the in vivo perfusion technology to
establish disease progression markers of DN in an animal
model of T1D. For this, we performed a comparative
proteomic analysis of the accessible proteins of kidneys in
the STZ model of non-insulin-treated rats by in vivo protein
biotinylation20,26 and mass spectrometry-based label-free
protein identification and quantification.27,28 The accessible
kidney proteomes of citrate-treated rats as well as rats termi-
nally perfused either 4, 8, or 12 weeks after STZ injection
were compared using the in-house-developed software suite
DeepQuanTR.29 The proteomic analysis resulted in the
identification and relative quantification of 396 proteins,
whereof 24 and 11 have been found more than 10-fold up- or
downregulated, respectively. Selected differentially regulated
proteins were validated by immunofluorescence detection in
rat kidney tissue. Interestingly, our results show typical
leakage pattern of the respective proteins into the urine of
patients with T1D and different levels of DN.
RESULTS
STZ-induced rat model of DN
Following STZ injection, animals developed severe diabetes
with very high postprandial blood glucose values compared
with citrate-treated control animals. At 12 weeks after citrate
injection, blood glucose was normal as assessed by the oral
glucose tolerance test. In contrast, STZ-treated rats showed a
slightly elevated glucose level after fasting and developed very
high serum glucose levels following oral glucose tolerance
test. The hyperglycemia was lowered only very slowly, and
was still high at 2 h after glucose gavage (Supplementary
Table S1 online).
Furthermore, STZ-induced diabetes resulted in severe
renal damage. Urinary albumin excretion rarely exceeded
250 mg/day in citrate-treated control rats, whereas animals
treated with STZ developed progressive albuminuria, reach-
ing a UAER of 1500 mg/day (Supplementary Table S1 online).
Albuminuria was accompanied by reduced renal excretory
function at 12 weeks after STZ treatment. Blood urea and
creatinine values were about four times higher in STZ rats
compared with normal values measured in citrate-injected
controls.
In vivo perfusion of rats and chemical proteomic analysis
Twenty-one-week-old rats at 4, 8, and 12 weeks after STZ
treatment as well as age-matched citrate-injected control rats
were subjected to a terminal perfusion procedure with a
0.5 mg/ml solution of the reactive biotin ester Sulfo-NHS-
LC-biotin (Pierce, Rockford, IL), followed by a quenching
step with a 50 mmol/l Tris-HCl solution. Immediately after
perfusion, the renal capsules were removed, the kidneys cut
in half, and the two halves separately frozen in liquid
nitrogen. After the first thawing, a cross-section was cut out
of the middle of each kidney half and embedded in OCT
Kidney International (2011) 80, 272–281 273
T Fugmann et al.: Biomarker of diabetic nephropathy o r ig ina l a r t i c l e
medium for histochemical analyses, whereas the rest of the
kidney was homogenized. The resulting protein extract was
loaded in the presence of 2% SDS onto a streptavidin-affinity
resin to purify biotinylated proteins. The following on-resin
tryptic protein digestion yielded proteolytic peptides suitable
for the mass spectrometry-based comparative proteomic
analysis (Figure 1a). Successful biotinylation of accessible
structures in the kidney was assessed by histochemical staining
of biotin using the streptavidin–biotinylated alkaline phospha-
tase complex and fast red as phosphatase substrate (Figure 1b).
Tryptic peptides derived from the on-resin digestion of
purified biotinylated proteins of individual kidneys were
separated by reversed-phase nanocapillary high-performance
liquid chromatography. The resulting fractions were mixed with
constant amounts of four internal standard peptides and matrix,
robotically spotted on MALDI-target plates (Foster City, CA)
and analyzed by MALDI-TOF (Foster City, CA) and MALDI-
TOF/TOF MS (Foster City, CA) for quantification and
identification purposes, respectively. The DeepQuanTR analysis
allowed the relative quantification of a total of 396 proteins
identified with at least two proteotypic peptides (Figure 2
and Supplementary Table S2 online). The number of identified
proteins is similar to experiments performed for the analysis of
tumors and normal organs in mice.20,21
The accessible kidney proteome of STZ-treated and
citrate-injected control rats
The chemical proteomic analysis revealed a number of
proteins with known expression on vascular endothelial cells,
in the apical and the lateral membrane area of podocytes, in
the glomerular basement membrane, and in the proximal
tubule (Table 1), defining therefore the kidney substructures
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Figure 1 | Schematic depiction of the chemical proteomic workflow and validation of the in vivo biotinylation efficacy. (a) The
abdomen of anesthetized rats was cut open and two ligations (L1 on the hepatic artery, L2 on the abdominal artery, and vein below the
branching points of the kidney arteries) were placed. Using a buttoned cannula, the kidneys were perfused through the aorta abdominalis
using a solution containing a reactive ester derivative of biotin. Following removal of the kidneys, tissue homogenization and protein
extraction, biotin-tagged proteins were enriched on a streptavidin-affinity resin. A tryptic on-resin digestion resulted in proteolytic peptides
submitted to the comparative proteomic analysis. B, biotin; SA, streptavidin. (b) The in vivo biotinylation efficacy was validated by a
histochemical staining of biotin using the streptavidin–biotinylated alkaline phosphatase complex and fast RED. Scale bars: 200 mm.
Cit, citrate-treated control; Neg, phosphate-buffered saline-perfused control rat; 4W, 8W, and 12W, 4, 8, and 12 weeks after streptozotocin
treatment.
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readily accessible for the charged biotinylation reagent used in
the perfusion experiments. During perfusion with the reactive
ester derivative of biotin and subsequently the quenching
solution soluble proteins are removed from the kidneys. Out of
the 396 identified and quantified proteins, 24 and 11 proteins
were found more than tenfold upregulated and downregulated
in the diseased kidneys compared with the citrate-treated
kidneys, respectively (Supplementary Figure S1 online). Some of
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Alpha-1-acid glycoprotein
Podocalyxin
Decorin
CD151 antigen
Alpha-actinin-4
Kin of IRRE-like protein 1
Protein tyrosine phosphatase D30
4F2 cell-surface antigen heavy chain
Neprilysin
Nephrin
Uromodulin
Alpha-3 type IV collagen
Solute carrier family 22 member 2
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GIutathione peroxidase 1
Figure 2 | List of selected proteins identified and quantified in this proteomic study. Besides differentially regulated proteins, a number
of proteins with known contribution to glomerulus diseases (for example, nephrin, podocalyxin, and CD151 antigen) were identified.
Antigens selected for further investigation are marked in bold. Protein abundances are displayed with a color code and the underlying
protein quant value (the protein quant value corresponds to the natural logarithm of the fold expression change). Proteins upregulated in
comparison with the average protein expression are displayed in green and downregulated proteins in red. Number of samples per group:
7. Cit, citrate-treated control; 4W, 8W, and 12W, 4, 8, and 12 weeks after streptozotocin treatment.
Table 1 | Localization of selected proteins identified in the comparative proteomic analysis of citrate-treated and STZ-induced
diabetic rats
Protein name Gene name SwissProt acc. nr. Location Reference
Platelet endothelial cell adhesion molecule Pecam1 Q3SWT0 EM Woodfin and co-workers50
Neuropilin-1 Nrp1 Q9QWJ9 EM Pellet-Many et al.51
Endothelial cell-selective adhesion molecule Esam Q6AYD4 EM Wong et al.52
Podocalyxin Podxl Q9WTQ2 AMP Aaltonen Holthofer53
Ezrin Ezr P31977 AMP Aaltonen Holthofer53
Protein tyrosine phosphatase D30 Ptpro Q62797 AMP Aaltonen Holthofer53
Low-density lipoprotein receptor-related protein 2 (megalin) Lrp2 P98158 AMP Aaltonen Holthofer53
Nephrin Nphs1 Q9R044 LMP Aaltonen Holthofer53
Kin of IRRE-like protein 1 Kirrel (Neph1) Q6X936 LMP Aaltonen Holthofer53
CD151 antigen Cd151 Q9QZA6 GBM Karamatic Crew et al.54
Agrin Agrn P25304 GBM Li et al.55
Neutral and basic amino-acid transport protein rBAT Slc3a1 Q64319 PT Raciti et al.56
Electrogenic sodium bicarbonate cotransporter 1 Slc4a4 Q9JI66 PT Raciti et al.56
Sodium/glucose cotransporter 2 Slc5a2 P53792 PT Raciti et al.56
Sodium-dependent neutral amino-acid transporter B(0)AT1 Slc6a19 Q2A865 PT Raciti et al.56
Solute carrier family 13 member 3 Slc13a3 Q9Z0Z5 PT Raciti et al.56
Solute carrier family 22 member 2 Slc22a2 Q9R0W2 PT Raciti et al.56
Solute carrier family 22 member 5 Slc22a5 O70594 PT Raciti et al.56
Solute carrier family 22 member 6 Slc22a6 O35956 PT Raciti et al.56
Abbreviations: AMP, apical membrane area of the podocyte; EM, endothelial membrane; GBM, glomerular basement membrane; LMP, lateral membrane area of the podocyte;
PT, proximal tubule; STZ, streptozotocin.
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these have previously been described to be involved and/or
regulated in DN (Supplementary Table S3 online).
Validation of accessible targets in DN
The selection of proteins used for the validation of the
DeepQuanTR results was based both on the protein regula-
tion determined by this proteomic investigation and on the
availability of antibodies recognizing the rat protein. Four
differentially regulated proteins (Figure 2, bold) were selected
for validation by immunofluorescence: (1) vanin-1 (Vnn1,
upregulated in diseased), (2) Ennp6 protein (Enpp6, upregu-
lated in diseased), (3) alpha-1-acid glycoprotein (Orm1,
slightly upregulated in diseased), and (4) uromodulin
(Umod, downregulated in diseased). The immunofluores-
cence analysis of rat kidney tissue derived from citrate-
injected control rats and the STZ-injected diabetic rats (4, 8,
and 12 weeks after STZ injection) confirmed the mass
spectrometry-based findings (Figure 3). Unfortunately, vanin-
1-specific antibodies that cross-react with the rat protein are
not commercially available. Antibodies against Enpp6 and
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Figure 3 |Validation of DeepQuanTR results. Immunostainings of kidney sections derived from citrate-injected control rats and
streptozotocin-injected diabetic rats killed at 4, 8, and 12 weeks after the end of the pharmacological treatment using antibodies against
Enpp6, Orm1, and Umod are presented. Additionally, negative controls omitting the primary antibody are shown (using only the secondary
anti-mouse antibody as negative control for Enpp6 and Umod, and only the secondary anti-rabbit antibody for Orm1). Antibodies against
Enpp6 and Umod stained tubular structures, whereas Orm1 was found in glomeruli. The differential expression of the three analyzed
proteins shown by immunostaining confirmed the results obtained by the proteomic analysis. Scale bars: 200 mm. Neg, negative.
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Umod stained tubular structures, whereas the anti-Orm1
antibody stained the glomeruli.
Analysis of protein expression in human urine
To investigate whether the differential protein expression of
the four selected regulated proteins could be translated to the
human pathology, urine sample pools derived from healthy
individuals and from T1D diabetes patients without
(o30 mg/day) and with highly (4300 mg/day) elevated
UAER were analyzed. To standardize the spot urine samples,
all urine pools were normalized to the creatinine concentra-
tion before analysis, analogous to standard clinical proce-
dures. Western blots of the three urine pools confirmed the
upregulation of Vnn1 and Umod in the macroalbuminuria
samples and in the diabetic samples, respectively (Figure 4).
Compared with albumin, which can be identified both in
urine of healthy individuals and diabetic patients (Figure 4),
uromodulin was found to be strongly upregulated in diabetic
samples and vanin-1 in samples of diabetic patients with
macroalbuminuria.
Analysis of protein expression in individual human urine
The urine of 6 healthy individuals and 10 diabetic patients
was collected for an analysis of interindividual variability of
VNN1 and UMOD excretion (Figure 5a). UMOD levels in all
diabetic patients were found to be elevated, similar to what
was observed in pooled urine samples. The increase was most
pronounced in diabetic patients with elevated UAER (Figure
5b). In contrast, the vanin-1 concentration in the urine
samples of individual patients was found to be highly variable
(Figure 5c). Patients with elevated UAER did not show a
significant increase of vanin-1 concentration in the urine.
Comparison with published microarray data
To get further insight into the mechanism of protein regu-
lation, we compared our proteomics findings with publicly
available microarray data (see Supplementary Materials
online).30,31 Owing to the different nature of the samples
(renal tubular cells for microarray experiments versus the cell
surface proteome of endothelial cells, podocytes, and tubular
cells, as well as extracellular matrix in the proximity of
these cells for our proteomic study), there was no global
correlation between the proteomics and the microarray data
(Supplementary Figure S2 online). Noteworthy, neither VNN1
nor UMOD was found to be significantly regulated in these
studies. Furthermore, microarrays used in both studies lacked
in probes against ENPP6. Although Rudnicki et al.30 analyzed
patient samples from proteinuric nephropathies, but not
from DN, we estimate that the lack of correlation emphasizes
the unique nature of the proteomics analysis presented here.
DISCUSSION
The proteomic analysis described in this article was based
on the terminal perfusion of citrate-treated rats and rats
treated with STZ using a reactive ester derivative of biotin
(Figure 1a). The terminal perfusion of rodents has previously
shown to be a useful technique to identify markers of tumor
neo-vasculature, which can be drugged with monoclonal
antibodies. The results of this study show that in vivo
biotinylation facilitates the detection of disease-specific
changes in the abundance of accessible proteins in rat
kidneys after STZ-induced diabetes. STZ is an analog of
N-acetylglucosamine, readily transported into pancreatic
b-cells by the glucose transporter GLUT-2 causing b-cell
toxicity, leading to insulin deficiency and elevated blood
glucose levels. A known limitation of this model is the
toxicity of STZ to renal tubular cells. For this study, the
standard STZ-induced diabetes model was modified to avoid
excessive initial toxic effects and thus to obtain a more
manageable diabetes. Further, the earliest time point for the
perfusion of rat kidneys was set to 4 weeks in which tubular
epithelial cells could regenerate.
Compared with citrate-treated control rats, which showed
normal UAERs of about 200 mg per 24 h, the UAER of
STZ-treated rats was in the range of 900–1500 mg per 24 h
(Supplementary Table S1 online), which is in line with values
previously published32 and which indicates severe kidney
damage. The successful in vivo protein biotinylation, which
was assessed by histochemistry, showed a uniform labeling
of glomeruli, blood vessels, and certain tubular structures
(Figure 1b). The subsequent mass spectrometry-based
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Figure 4 |Validation of selected proteins in human urine.
(a) Western blot analyses using urine derived from healthy
individuals and from diabetic patients with normal urinary
albumin excretion (normo) and with macroalbuminuria (macro)
were performed using antibodies against VNN1, UMOD, and ALB.
(b) A Ponceau S-stained western blot of creatinine-normalized
urines is shown. The albumin band is indicated with an
arrowhead.
Kidney International (2011) 80, 272–281 277
T Fugmann et al.: Biomarker of diabetic nephropathy o r ig ina l a r t i c l e
proteomic analysis resulted in the identification and label-
free relative quantification of 396 proteins, whereof 24 and
11 proteins were found more than 10-fold upregulated and
downregulated in the diseased kidneys compared with the
healthy citrate-treated kidneys, respectively (Figure 2, Supple-
mentary Figure S1 online and Supplementary Table S2 online).
Several proteins could be mapped to distinct locations in
the kidney, such as the glomerular basement membrane, the
apical as well as the lateral membrane of the podocyte, the
endothelial membrane, and the proximal tubule (Table 1),
thereby defining the kidney substructures in which proteins
were chemically modified by the reactive ester derivative
of biotin. Importantly, most serum components, such as
albumin (a known marker for accelerated plasma protein
leakage across the glomerular basement membrane in DN),
transferrin, and fibrinogen, were not found to be regulated
in this proteomic analysis. In contrast, serum components,
which were previously identified to be either upregulated in
the serum of patients with diabetes (kallikrein,33 hapto-
globin,34 and coagulation factor XII33) or to be associated
with DN (kininogen 1 (ref.35)), were found among the most
differentially expressed proteins.
The upregulated proteins vanin-1 (Vnn1), Enpp6 protein
(Enpp6), and alpha-1-acid glycoprotein (Orm1) were further
validated. Although no correlation between the upregulation
of Enpp6 and diabetes or DN was found in literature, the
upregulation of Vnn1 in T1D36 and of Orm1 in DN37 has
previously been described. An immunofluorescence analysis
of Enpp6 and Orm1 on rat kidney section revealed their
upregulation in tubular structures and glomeruli in STZ-
treated diabetic rats, respectively (Figure 3).
Orm1 could be detected by immunofluorescence staining,
which was also confirmed by western blot of rat kidney tissue
homogenates (data not shown) but could not be detected in
human urine samples.
Enpp6 was found to be expressed on tubular epithelium in
kidney sections from STZ-treated rats, but both commercial
antibodies tested were reactive against human immuno-
globulin G heavy chain, as demonstrated by western blot,
detecting purified human immunoglobulin G (data not
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Figure 5 |Quantitative assessment of VNN1 and UMOD in individual urine samples. (a) Western blot analyses using urine from healthy
individuals (healthy), patients with T1D but normal albumin excretion rates (T1D), and patients with elevated (DN1) and pronounced
(DN2) urinary albumin excretion rate (UAER) were performed with antibodies against UMOD, VNN1, and ALB. VNN1 (b) and UMOD
(c) bands were quantified using image J software (US National Institutes of Health, Bethesda, MD). The area under the curve of bands from
individual urine samples is displayed as circles, whereas the average in a pathological group is displayed with a horizontal line. For
this analysis, all diabetic patients with elevated UAER were included in one group (T1DDN) to have a higher number of measurements
per group.
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shown). Owing to the similar size of the heavy chain
(B55 kDa) and ENPP6 (B52 kDa), and the upregulation of
human immunoglobulin G fragments in DN, it was impos-
sible to discriminate between specific and nonspecific signals.
Interestingly, ENPP6 was identified in a study of urinary
exosomes,38 suggesting that this protein is also expressed in
healthy kidneys, making it a top candidate for follow-up
studies.
Although the immunofluorescence staining of Vnn1 could
not be performed because of the unavailability of antibodies
recognizing the rat protein, it showed to be upregulated in
pooled urine of T1D patients with macroalbuminuria
(Figure 4). In contrast, the analysis of spot urine from
individual patients presented a variable VNN1 concentration,
without a significant upregulation in DN patients. These
findings could be explained in terms of patient improvement
as a result of pharmacological intervention (formerly overt
albuminuria indeed reverted to UAER below 300 mg/l).
Alternatively, if this protein is indeed of tubular origin, timed
urine collections should be considered, as recently pro-
posed,39 to more reliably assess the rate of protein release.
Both issues can only be resolved by studying a larger patient
population, with additional time points for urine collection.
Uromodulin (UMOD; also known as Tamm–Horsfall
urinary glycoprotein) was identified in the proteomic analysis
to be downregulated in the diabetic rat samples when
compared with the citrate-treated control rats. This is in line
with the observation of Chakraborty and co-workers40 who
showed that a decreased immunogold labeling of UMOD in
human kidney specimens is associated with renal damage and
with our immunofluorescence analysis on rat kidneys (Fig-
ure 3). The upregulation of UMOD in individual and pooled
patient urine (Figure 4) seems to be contradictory at first but
can be explained by its shedding into the urine, which was
proposed to have a role in water/salt balance.41 The observation
that this balance is altered in DN suggests that uromodulin
shedding is increased under pathological condition.42,43
In this proteomics-based study of a T1D rat model and
its complications, we have identified 396 proteins and
followed their expression over a time course of 12 weeks.
The protein most significantly upregulated in the diabetic
rats was vanin-1, a glycosylphosphatidylinositol-anchored
epithelial pantetheinase, which has proinflammatory and
cytoprotective effects in some tissues.44,45 Modulation of the
vanin-1 activity has been suggested as alternative strategy to
maintain islet cell homeostasis.36 Although vanin-1 is indeed
upregulated in a pool of urine from patients with macro-
albuminuria, an analysis of individual urine samples showed
large interindividual variability, indicating the need for
dedicated studies with large numbers of individual urine
samples to properly assess the value of this candidate marker
for the monitoring of DN progression in patients.
Recently, serum cystatin C has been proposed for the
early detection of DN,46 and is currently evaluated for the
detection of mildly to moderately impaired kidney function
in diabetic patients. In full analogy to the development of
cystatin C, vanin-1 could be validated as marker for the early
detection of impaired kidney function in diabetes patients.
For this purpose, large-scale studies using clinically validated
urine samples of healthy individuals and diabetic patients
with different stages of impaired renal function have to be
carried out. To perform such studies, specific high-affinity
monoclonal antibodies as well as validated antibody-based
tests (for example, enzyme-linked immunosorbent assay) are
essential and have to be developed, challenges which are
clearly beyond the scope of this study.
MATERIALS AND METHODS
Animals
Nine-week-old male Sprague–Dawley rats (Charles River, Wilmington,
MA) with known sensitivity to STZ-induced diabetes weighing
268±11 g were used. All animals were housed under standard
conditions (light on 08:00–20:00 h; 40–70% relative humidity,
22±1 1C), and had free access to water and chow (Altromin
standard diet, Lange, Germany). All procedures were in accordance
with the guidelines of the Institutional Animal Care and Use
Committee of the Semmelweis University.
DN model
STZ diabetes was induced, as described previously.47 Briefly,
rats obtained a single intraperitoneal injection of 55 mg STZ
(N-(methylnitrosocarbamoyl)-a-D-glucosamine; Sigma-Aldrich,
St Louis, MO) per kg body weight dissolved in citrate buffer (pH
4.5). Rapid administration of STZ and solution pH is important to
achieve diabetes. A total of 17 animals were stratified into four
groups (n¼ 4/group) with equal average initial body weight: four
groups of animals were injected with STZ, and 5 age-matched
control rats were injected with the citrate buffer only.
In vivo biotinylation
In vivo biotinylation experiments were performed similarly, as
previously described.20,26 Briefly, rats were anesthetized with a
combination of ketamin (Ve´toquinol, Ittingen, Switzerland), xylazin
(Streuli, Uznach, Switzerland), and acepromazine (Arovet, Dietikon,
Switzerland). The abdomen was opened and two ligations
(the first on the abdominal artery and vein below the branching
points of the kidney arteries and the second on the hepatic artery)
were placed. Following a median sternotomy, a buttoned cannula
was inserted into the aorta abdominalis and fixed with medical wire.
To allow the biotinylation reagent to flow out, the vena cava was cut
open. The perfusion was carried out at 150 mm Hg column using
20 ml prewarmed (40 1C) biotinylation solution (0.5 mg/ml Sulfo-
NHS-LC-Biotin (Pierce) and 10% Dextran-40 (GE Healthcare,
Chalfont St Giles, UK) in phosphate-buffered saline, followed by
20 ml of prewarmed (40 1C) quenching solution (50 mmol/l
Tris-HCl and 10% Dextran-40 in phosphate-buffered saline). After
perfusion, kidneys were excised, cut in half, and separately freshly
snap frozen in liquid nitrogen-cooled isopentane for preparation of
organ homogenates. A total of nine STZ rats and five citrate-treated
control rats were terminally perfused. An unperfused citrate-treated
rat was used as negative control for the proteomic analysis.
Purification of biotinylated proteins and proteomic analysis
Purification of biotinylated proteins on streptavidin resin, the
tryptic on-resin digestion, and the subsequent proteomic analysis of
resulting tryptic peptides were performed according to standard
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procedures.22,48 A detailed description can be found in the Supple-
mentary Materials online.
Relative protein quantification by DeepQuanTR software
The DeepQuanTR software has been described in detail elsewhere.29
Briefly, after mass spectrometry acquisition, data related to the
individual peaks (fractions, intensities, and mass-to-charge ratios) were
loaded into the DeepQuanTR software, which performed a normal-
ization of individual signal intensities to the internal standard peptides
and an annotation (peptide identification and association with a parent
protein). Normalized intensities for the individual peptides from
all samples of each group (that is, citrate control, 4, 8, and 12 weeks
after STZ injection) were used for the computation of DeepQuanTR
peptide and protein scores, indicating the relative abundance of
individual peptides and proteins in the various groups of samples.
Human urine samples
Human urine samples from healthy individuals were obtained from
male volunteers of the lab (midstream morning urine, supplemented
with 1 complete proteinase inhibitor cocktail (Roche Diagnostics,
Mannheim, Germany), centrifuged at 3300 g for 10 min at 4 1C,
and the supernatant was aliquoted and stored at 80 1C). Human
urine from patients with T1D were obtained from the Finnish
Diabetic Nephropathy (FinnDiane) Study.49 Six patients with
normal albumin excretion rate (o30 mg/24 h) and six with
macroalbuminuria (4300 mg/24 h) provided urine for two pools
of urine, respectively. All patients exhibited similar creatinine
concentrations. The pools were aliquoted and stored at 20 1C.
For the analysis of interindividual variability of VNN1 and
UMOD levels, urine of 10 additional patients was collected,
as described above. Five patients were diabetic with UAER
o30 mg/l and two patients exhibited elevated albumin levels
(430; o200 mg/l). Three patients suffered from overt albuminuria
but because of successful medication, their UAER fell below the
threshold of macroalbuminuria at the time of sample collection. All
relevant data for the 16 individual urine donors can be found in
Supplementary Table S5 online.
A detailed description of the functional measurements, the
histochemistry, the preparation of protein extracts, the purification
of biotinylated proteins, the proteomic analysis, the immuno-
fluorescence analysis (Supplementary Table S4 online), and the western
blot analysis can be found in the Supplementary Materials online.
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